PIQUR Therapeutics Stock
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Sign up today and learn more about PIQUR Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About PIQUR Therapeutics Stock
PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the University of Basel, focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. Both PI3K and mTOR are clinically validated drug targets in oncology. PIQUR has a secured patent scope protecting many chemical compounds.
Funding History
| August 2013 | $5.0M |
|---|---|
| March 2014 | $32.0M |
| July 2015 | $19.0M |
| September 2017 | $29.8M |
Management
Chief Scientific Officer
Doriano Fabbro
Head BD & Communications
Tatsuo Satoh
Head Drug Discovery
Paul Hebeisen
Head of Preclinical Safety & Toxicology
Robert Ettlin
COO/CMO
Melanie Rolli
CFO
Martin Gasser
Head QA
Christine Wurz
Press
patents - Apr, 14 2024
Treatment of skin lesionsartrocker - Dec, 19 2023
Cancer Janus Kinase Inhibitors Market Size, Share, Scope ...artrocker - Dec, 19 2023
Cancer mTOR Inhibitors Market Size, Predicting Trends and ...startupticker - Jul, 11 2018
Versant Ventures invests CHF 11 million in PIQURstartupticker - Apr, 30 2017
Additional milestone for PIQUR's lead compoundEquityZen Recognized As:
